Abstract
Background Plasma biomarkers showed a promising value in the disease diagnosis and management of Alzheimer’s disease (AD). However, profiles of the biomarkers and the association with cognitive domains along the spectrum of cognitive performance deterioration have seldom been reported.
Methods We recruited 320 individuals with cognitive impairment and 131 cognitively normal participants from a memory clinic and a community cohort. Participants were classified into 6 groups based on their Clinical Dementia Rating (CDR) scores and clinical diagnosis of AD, amnestic mild cognitive impairment, and normal cognition (NC). Each participant was administered the neuropsychological tests assessing the global and domain-specific cognition. Plasma Aβ1-40, Aβ1-42, Aβ1-42/Aβ1-40, total tau (t-tau), neurofilament protein light chain (NfL), and phosphorylated tau at threonine 181 (p-tau181) were quantified using the Single molecule array platform.
Results Along with plasma Aβ1-40, Aβ1-42, Aβ1-42/Aβ1-40, t-tau, and NfL, p-tau181 significantly increased across the groups with the incremental CDR scores from NC (CDR = 0) to severe AD (CDR = 3). Compared with other biomarkers, p-tau181 had a stronger correlation with Global cognition (r = −0.494, P < 0.001), Memory (r = −0.417, P < 0.001), Attention (r = −0.388, P < 0.001), Visuospatial function (r = −0.328, P < 0.001), and Language (r = −0.123, P = 0.014). Among AD participants with CDR ≥ 1, higher p-tau181 was correlated with worse Global cognition (r = −0.295, P < 0.001), Memory (r = −0.172, P = 0.045), and Attention (r = −0.184, P = 0.031).
Conclusions Plasma p-tau181 had a stronger correlation with cognitive domains than other biomarkers, especially in late-stage AD. It could reflect the AD pathology in vivo and may be a promising blood-based biomarker in clinical settings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants of Clinical Research Plan of SHDC (No. SHDC2020CR4007), Key projects of special development funds for Shanghai Zhangjiang National Innovation Demonstration Zone (201905-XH-CHJ-H25-201), MOE Frontiers Center for Brain Science (JIH2642001/028), Scientific Research Plan Project of Shanghai Science and Technology Committee (17411950106, 17411950701), National Project of Chronic Disease (2016YFC1306402), National Natural Science Foundation of China (82071200, 81773513, 21874091, 31927803), and Shanghai Municipal Science and Technology Major Project (2018SHZDZX01) and ZJLab.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Medical Ethics Committee of Huashan Hospital, Fudan University, Shanghai, China (No. 2009-195 and 2011-288)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Abbreviations
- AD
- Alzheimer’s disease
- aMCI
- amnestic mild cognitive impairment
- aMCI-m
- amnestic mild cognitive impairment multi-domains
- aMCI-s
- amnestic mild cognitive impairment single-domain
- ANOVA
- Analysis of Variance
- APOE
- Apolipoprotein E
- CDR
- Clinical Dementia Rating
- CSF
- cerebrospinal fluid
- EDTA
- Ethylene Diamine Tetraacetic Acid
- MCI
- mild cognitive impairment
- MMSE
- Mini-mental State Examination
- MoCA-B
- Montreal Cognitive Assessment-Basic
- NC
- normal cognition
- NfL
- neurofilament protein light chain
- PET
- positron emission tomography
- p-tau181
- phosphorylated tau 181
- SAS
- Shanghai Aging Study
- SD
- standard deviation
- Simoa
- Single molecule array
- TMT
- Trail Making Test
- t-tau
- total tau
